secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHAMPIONS ONCOLOGY, INC. (CSBR)
CIK:        0000771856
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001628280-23-025452
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Champions Oncology reports Q4 revenue $13.1M (+2% YoY); full-year record $53.9M but operating loss widens
--------------------------------------------------------------------------------

- Q4 operating loss of $2.5M vs $311K loss a year ago; includes $807K asset impairment on Lumin platform.
- Full-year operating loss $5.3M vs income $607M; adjusted EBITDA loss $1.3M vs +$3.1M.
- Gross margin fell to 44% (Q4) and 45% (FY) from 52% in prior-year periods due to study cancellations.
- Cash $10.1M, no debt; CFO projects return to profitability in H2 of current fiscal year.
- Announced formation of wholly owned biotech subsidiary Corellia AI for therapeutic drug discovery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/771856/000162828023025452/0001628280-23-025452-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/771856/000162828023025452/csbr-20230724.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-025452

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer